Literature DB >> 32671994

CRISPR/Cas9-mediated double knockout of SRPK1 and SRPK2 in a nasopharyngeal carcinoma cell line.

Pongphol Prattapong1, Chawalit Ngernsombat1, Sathid Aimjongjun1, Tavan Janvilisri2.   

Abstract

BACKGROUND: Serine-arginine protein kinase (SRPK) is a regulator of alternative splicing events via phosphorylation of splicing factor proteins. Oncogenic roles of SRPK1 and SRPK2 have been reported in various types of cancer. To date, only SRPK1/2 specific inhibitors and small interfering RNA (siRNA) have been used for halting their function momentarily; however, there is no attempt to generate SRPK1/2 stable knockout cancer cells as a tool to investigate their roles in tumorigenesis. AIM: Our objective is therefore to establish a nasopharyngeal carcinoma (NPC) cell line with stable SRPK1 or SRPK2 knockout and SRPK1/2 double knockout as a model to investigate their potential roles in NPC. METHODS AND
RESULTS: CNE1 was selected as a representative of NPC cell lines to create single and double knockout of SRPK1/2 proteins. SRPK1/2 KO plasmid with cas9, green fluorescent protein (GFP), and gRNA expression was cotransfected with SRPK1/2 homology-directed repair (HDR) plasmid containing puromycin resistance, red fluorescent protein (RFP), and 5' and 3' arm sequence for homologous recombination to CNE1 cells. The transfected CNE1 cells with GFP and RFP expression were sorted through fluorescence-activated cell sorting for further treatment with puromycin containing medium. This step generated stable single knockout of SRPK1 and SRPK2. The SRPK2 knockout NPC cells were used as a precursor for double knockout generation via transfection with Cre plasmid for excision of inserted material to generate puromycin-sensitive SRPK2 knockout clone. The puromycin-sensitive SRPK2 knockout cells were transfected with SRPK1 KO/HDR plasmid and treated with puromycin-containing medium. The puromycin-resistant cells of SRPK1/2 stable double knockout were expanded, and the corresponding protein expression was confirmed by western immunoblotting analysis.
CONCLUSION: Single and double knockout of SRPK1/2 were established using clustered regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated 9 (Cas9) system in an NPC cell line as a model for investigation of their splicing mechanism in NPC.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  CRISPR/Cas9; SRPK1; SRPK2; alternative splicing; nasopharyngeal carcinoma

Year:  2019        PMID: 32671994      PMCID: PMC7941449          DOI: 10.1002/cnr2.1224

Source DB:  PubMed          Journal:  Cancer Rep (Hoboken)        ISSN: 2573-8348


  16 in total

Review 1.  Treatment approaches to nasopharyngeal carcinoma: a review.

Authors:  Francesco Caponigro; Francesco Longo; Franco Ionna; Francesco Perri
Journal:  Anticancer Drugs       Date:  2010-06       Impact factor: 2.248

2.  Genome Editing in Mammalian Cell Lines using CRISPR-Cas.

Authors:  Kaiwen Ivy Liu; Norfala-Aliah Binte Sutrisnoh; Yuanming Wang; Meng How Tan
Journal:  J Vis Exp       Date:  2019-04-11       Impact factor: 1.355

Review 3.  Review of nasopharyngeal carcinoma.

Authors:  Anita Jeyakumar; Todd M Brickman; Alwin Jeyakumar; Timothy Doerr
Journal:  Ear Nose Throat J       Date:  2006-03       Impact factor: 1.697

4.  CRISPR/Cas9-mediated double knockout of SRPK1 and SRPK2 in a nasopharyngeal carcinoma cell line.

Authors:  Pongphol Prattapong; Chawalit Ngernsombat; Sathid Aimjongjun; Tavan Janvilisri
Journal:  Cancer Rep (Hoboken)       Date:  2019-11-27

5.  Up-regulation of SRPK1 in non-small cell lung cancer promotes the growth and migration of cancer cells.

Authors:  Hongcheng Liu; Xuefei Hu; Yuming Zhu; Gening Jiang; Sheng Chen
Journal:  Tumour Biol       Date:  2015-12-14

6.  SRPK2 promotes the growth and migration of the colon cancer cells.

Authors:  Jian Wang; Hai-Feng Wu; Wei Shen; Dong-Yan Xu; Ting-Yan Ruan; Guo-Qing Tao; Pei-Hua Lu
Journal:  Gene       Date:  2016-04-12       Impact factor: 3.688

7.  SRPKIN-1: A Covalent SRPK1/2 Inhibitor that Potently Converts VEGF from Pro-angiogenic to Anti-angiogenic Isoform.

Authors:  John M Hatcher; Guowei Wu; Chuyue Zeng; Jie Zhu; Fan Meng; Sherrina Patel; Wenqiu Wang; Scott B Ficarro; Alan L Leggett; Chelsea E Powell; Jarrod A Marto; Kang Zhang; Jacky Chi Ki Ngo; Xiang-Dong Fu; Tinghu Zhang; Nathanael S Gray
Journal:  Cell Chem Biol       Date:  2018-02-22       Impact factor: 8.116

8.  Development of Potent, Selective SRPK1 Inhibitors as Potential Topical Therapeutics for Neovascular Eye Disease.

Authors:  Jennifer Batson; Hamish D Toop; Clara Redondo; Roya Babaei-Jadidi; Apirat Chaikuad; Stephen F Wearmouth; Brian Gibbons; Claire Allen; Cynthia Tallant; Jingxue Zhang; Chunyun Du; Jules C Hancox; Tom Hawtrey; Joana Da Rocha; Renate Griffith; Stefan Knapp; David O Bates; Jonathan C Morris
Journal:  ACS Chem Biol       Date:  2017-02-06       Impact factor: 5.100

9.  SRPK1 is a poor prognostic indicator and a novel potential therapeutic target for human colorectal cancer.

Authors:  Nan Yi; Mingbing Xiao; Feng Jiang; Zhaoxiu Liu; Wenkai Ni; Cuihua Lu; Runzhou Ni; Weichang Chen
Journal:  Onco Targets Ther       Date:  2018-09-03       Impact factor: 4.147

Review 10.  Off-target Effects in CRISPR/Cas9-mediated Genome Engineering.

Authors:  Xiao-Hui Zhang; Louis Y Tee; Xiao-Gang Wang; Qun-Shan Huang; Shi-Hua Yang
Journal:  Mol Ther Nucleic Acids       Date:  2015-11-17       Impact factor: 10.183

View more
  4 in total

Review 1.  CRISPR/Cas9 application in cancer therapy: a pioneering genome editing tool.

Authors:  Roozbeh Moghaddar; Amirhossein Fakhre Yaseri; Sadegh Shojaei Baghini; Zhanna R Gardanova; Saeme Azizi Hassan Abadi; Burhan Abdullah Zaman; Ahmet İlhan; Navid Shomali; Ali Adili
Journal:  Cell Mol Biol Lett       Date:  2022-05-04       Impact factor: 8.702

2.  CRISPR/Cas9-mediated double knockout of SRPK1 and SRPK2 in a nasopharyngeal carcinoma cell line.

Authors:  Pongphol Prattapong; Chawalit Ngernsombat; Sathid Aimjongjun; Tavan Janvilisri
Journal:  Cancer Rep (Hoboken)       Date:  2019-11-27

3.  Intracellular Fate and Impact on Gene Expression of Doxorubicin/Cyclodextrin-Graphene Nanomaterials at Sub-Toxic Concentration.

Authors:  Daniela Caccamo; Monica Currò; Riccardo Ientile; Elisabetta Am Verderio; Angela Scala; Antonino Mazzaglia; Rosamaria Pennisi; Maria Musarra-Pizzo; Roberto Zagami; Giulia Neri; Consolato Rosmini; Monica Potara; Monica Focsan; Simion Astilean; Anna Piperno; Maria Teresa Sciortino
Journal:  Int J Mol Sci       Date:  2020-07-10       Impact factor: 5.923

4.  FOXP4-AS1 May be a Potential Prognostic Biomarker in Human Cancers: A Meta-Analysis and Bioinformatics Analysis.

Authors:  Guangming Zhang; Yongfeng Wang; Xiaoyong Han; Tingting Lu; Liangyin Fu; Haojie Jin; Kehu Yang; Hui Cai
Journal:  Front Oncol       Date:  2022-05-26       Impact factor: 5.738

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.